Nevertheless, while miR-122 restoration in association with sorafenib did not improve drug sensitization of SerpinB3-overexpressing HCC cells, it is conceivable that other combinations, such as those with TP53-interacting chemotherapies, might be more effective in this subgroup of patients. The gene discussed is SERPINB3; the disease is hepatocellular carcinoma.